,pathwayID,numbers
0,5-HETE,1
1,H2O,54
2,5-HETEL,1
3,"ADRB1,2,3:β-blockers",20
4,"ADRB1,2,3",20
5,β-blockers,20
6,urate,4
7,ADIPOQ trimer:ADIPOR dimers,2
8,ADIPOQ trimer,2
9,ADIPOR dimers,2
10,TLR4:LY96:S100A8:S100A9,8
11,TLR4:LY96,9
12,S100A8:S100A9,8
13,PPi,6
14,ACA-CoA,2
15,AMP,3
16,ATP,49
17,CoA-SH,15
18,ACA,2
19,HSCN,3
20,PYR,3
21,sulfanegen,3
22,HCN,3
23,RFNA,3
24,hydroquinone,3
25,RFDHN,3
26,quinone,3
27,CR:atREs,4
28,NADP+,12
29,TMAO,2
30,O2,20
31,H+,15
32,TMA,2
33,NADPH,12
34,13-HDHA,2
35,DHA,2
36,"NR1H2,3:RXR:NR1H2,3 ligand:ABCG5 gene",1
37,ABCG5 gene,1
38,"NR1H3, NR1H2 ligands",4
39,"NR1H2,3:RXR",3
40,"NR1H2,3:RXR:NR1H2,3 ligand:ABCG8 gene",1
41,ABCG8 gene,1
42,"TFAP2A,TFAP2C homodimers:CITED2:PITX2 Gene",1
43,"TFAP2A,TFAP2C homodimers:CITED2",1
44,PITX2 Gene,1
45,ADP,40
46,"p-S23,S24-TNNI3",2
47,TNNI3,2
48,JAG1:NOTCH2,2
49,JAG1,4
50,NOTCH2/Fringe-modified NOTCH2,2
51,"LPA,PA",3
52,"MAG,DAG",3
53,L-PCARN,1
54,CAR,5
55,PALM-CoA,1
56,HCO3-,5
57,Cl-,22
58,Glc,8
59,SLC22A18 substrates,2
60,L-Asp,2
61,L-Glu,2
62,GPIHBP1:HSPG:LPL dimer,5
63,GPIHBP1,5
64,HSPG:LPL dimer,1
65,Na+,18
66,p-S16-PLN pentamer,2
67,PLN pentamer,2
68,K+,18
69,CIT,2
70,PEP,2
71,Cleaved fibrillin-1,1
72,Fibrillin-1,1
73,RAS mutants:GTP:p-RAF homo/heterodimer,2
74,"p-T,Y MAPKs",3
75,RAF/MAPK scaffolds,4
76,p-2S MAP2K homo/heterodimers,3
77,"mutant RAS:GTP:p-RAF:p-2S MAP2Ks:p-T,Y MAPKs:scaffold proteins",2
78,Heparan sulfate chain,1
79,HS core proteins,1
80,HS/HPIN-PGs,1
81,ZFPM proteins:GATA proteins,1
82,GATA proteins,1
83,"ZFPM1, ZFPM2",1
84,BRAF inhibitors:high kinase activity BRAF mutants,3
85,BRAF inhibitors,3
86,high kinase activity BRAF mutants,5
87,ARL6:GTP:BBSome:ciliary cargo,2
88,ARL6:GTP,2
89,BBSome,4
90,BBSome ciliary cargo,2
91,chondroitin(2)-core proteins,2
92,UDP,3
93,UDP-GlcA,2
94,chondroitin(1)-core proteins,2
95,DSCAM:p-S144-PAK1:RAC1:GTP,1
96,p-S144-PAK1:RAC1:GTP,1
97,DSCAM,2
98,"Ubiquitinated,hyperphosphorylated RNA Pol II:Damaged DNA template:nascent mRNA hybrid:TFIIH:Ub:ERCC6:ERCC8:DDB1:CUL4:RBX1",3
99,Ub,1
100,Hyperphosphorylated RNA Pol II:Damaged DNA template:nascent mRNA hybrid:TFIIH:ERCC6:ERCC8:DDB1:CUL4:RBX1,1
101,Ac-Cohesin:PDS5:WAPAL:Centromere,2
102,Cohesin:PDS5:WAPAL:Centromere,2
103,Ac-CoA,7
104,FGFR2c mutant dimers with enhanced ligand-binding bound to FGFs,1
105,FGFR2c mutant binding FGFs,1
106,HS,4
107,FGFR2c mutants with enhanced ligand binding,1
108,CDC42:GTP:p-Y-WASP/p-Y-WASL:WIP:SH3 proteins,1
109,CDC42:GTP:WASP/N-WASP:WIP:SH3 proteins,2
110,2'-deoxynucleoside,1
111,PPPi,1
112,dNTP(4-),1
113,L-Orn,2
114,L-Cit,2
115,FGFR2b mutant dimers with enhanced ligand-binding bound to FGFs,1
116,FGFR2b mutant-binding FGFs,1
117,FGFR2b mutants with enhanced ligand binding,1
118,Activated FGFR2 ligand-independent mutants,1
119,FGFR2 ligand-independent mutant dimers,3
120,"Ubiquitinated,hyperphosphorylated RNA Pol II:Damaged DNA template:nascent mRNA hybrid:TFIIH:Ub:ERCC6:ERCC8:DDB1:CUL4:RBX1:UVSSA:USP7:XAB2 complex:XPA:TCEA1:HMGN1:EP300",2
121,HMGN1,2
122,XPA,2
123,EP300,2
124,TCEA1,2
125,XAB2 complex,2
126,UVSSA:USP7,2
127,WIP family proteins,1
128,SH3 domain proteins,1
129,CDC42:GTP:WASP/N-WASP,1
130,TC-NER pre-incision complex:Open bubble damaged DNA template:RPA:ERCC5:trimmed nascent mRNA,1
131,RPA heterotrimer,2
132,TC-NER pre-incision complex:Open bubble damaged DNA template:trimmed nascent mRNA,2
133,ERCC5,2
134,DSCAM/DSCAML1 homodimers,1
135,"DSCAM, DSCAML1",1
136,Fru 1-P,1
137,Fru,1
138,Ac-Cohesin:PDS5:WAPAL:Chromosomal Arm,1
139,Cohesin:PDS5:WAPAL:Chromosomal Arm,1
140,Telomerase RNP,3
141,NOP10,2
142,DKC1,2
143,Telomerase RNA Component (TERC),2
144,TERT,2
145,GAR1,2
146,WRAP53,2
147,NHP2,2
148,Pi,10
149,TC-NER pre-incision complex,1
150,SUCCA,9
151,CO2,14
152,Lysyl hydroxylases:Lysyl hydroxylated collagen propeptides,2
153,Lysyl hydroxylases:Lysyl hydroxylase procollagen substrates,2
154,2OG,9
155,Activated FGFR1 mutants and fusions:PLCG1,2
156,"PI(3,4,5)P3",11
157,Activated FGFR1 mutants and fusions,2
158,PLCG1,11
159,Activated FGFR3 mutants: PLCG1,3
160,Activated FGFR3 mutants,4
161,Activated FGFR2 mutants:PLCG1,3
162,Activated FGFR2 mutants,4
163,Activated FGFR4 mutants:PLCG1,3
164,Activated FGFR4 mutants,4
165,acetylated microtubule,2
166,Microtubule,2
167,SPRED dimer:NF1,1
168,SPRED dimer,1
169,NF1(2-2839),1
170,dNTP,2
171,"3' overhanging ssDNA-DSBs:p-MRN:p-S1981,Ac-K3016-ATM:KAT5:BRCA1-C complex:EXO1,DNA2:BLM,WRN:p-S990,Ac-K1249-BRIP1",1
172,"3' short overhanging ssDNA-DSBs:p-MRN:p-S1981,Ac-K3016-ATM:KAT5:BRCA1-C complex:EXO1,DNA2:BLM,WRN:p-S990,Ac-K1249-BRIP1",1
173,GLI:SUFU,3
174,"GLI1,2,3",3
175,SUFU,3
176,MECP2:FOXG1,1
177,FOXG1,1
178,MECP2,1
179,p-2S-SMAD2/3:SMAD4:MEN1,1
180,p-2S-SMAD2/3:SMAD4,1
181,MEN1,1
182,NTP,11
183,DSIF:NELF:early elongation complex,4
184,RNA Pol II (hypophosphorylated) complex bound to DSIF protein,4
185,NELF complex,4
186,BTN2A1:CD209,3
187,BTN2A1,3
188,CD209,3
189,Telomerase RNP:G-strand telomeric chromosome end,1
190,Telomeric G-strand chromosome end:Shelterin,1
191,RTEL1,1
192,MECP2:DGCR8,2
193,DGCR8,2
194,p-S80-MECP2,2
195,"GPCHO, GPETAM",1
196,fatty aldehyde,1
197,"PMCHO, PMETAM",1
198,"PI(4,5)P2:p-T156 AP-2:clathrin:ITSNs:EPS15:REPS1:SGIP1:NECAPs:AAK1:CLASP proteins:cargo:F-BAR proteins:BAR domain proteins:ARP2/3 complex:WASL:f-actin:HIP dimers",1
199,ARP2/3 complex,1
200,HIP1 dimer,1
201,HIP1R dimer,1
202,f-actin,1
203,"WASL,CTTN",1
204,"PI(4,5)P2:p-T156 AP-2:clathrin:ITSNs:EPS15:REPS1:SGIP1:NECAPs:AAK1:CLASP proteins:cargo:F-BAR proteins:BAR domain proteins",1
205,"ABCG1 gene:NR1H2,3:RXR:oxysterol:GPS2:KDMs",1
206,GPS2,1
207,"KDM1A, KDM1B, KDM3A, KDM4A",1
208,ABCG1 gene,1
209,"EDNRA,EDNRB:Endothelin",3
210,"EDNRA,EDNRB",3
211,Endothelin,3
212,NTF3:p-5Y-NTRK3 homodimer,1
213,NTF3:NTRK3 homodimer,1
214,H2O2,4
215,PA,1
216,1-acyl LPA,1
217,acyl-CoA,2
218,P2RY12:P2RY12 antagonists,9
219,P2RY12 antagonists,9
220,P2RY12,9
221,ARBs:AGTR1,8
222,ARBs,8
223,AGTR1,8
224,Lp(a),2
225,LPA,2
226,LDL,6
227,ACEIs:ACE(30-1232),9
228,ACE(30-1232),9
229,ACEIs,9
230,SCUBE3(?-993),4
231,SCUBE3(21-?),4
232,SCUBE3,4
233,Ca2+,12
234,TPH1 gene:EGR1,1
235,TPH1 gene,1
236,EGR1,1
237,Virion with gp41 forming hairpin structure,1
238,Virion with gp41 fusion peptide in insertion complex,1
239,CUBN:AMN:GIF:Cbl,1
240,GIF:Cbl,1
241,CUBN:AMN,1
242,GG-NER pre-incision complex:Open bubble-dsDNA,1
243,"Open bubble-dsDNA:PAR-UV-DDB:TFIIH Core:XPA:PAR-PARP1, PAR-PARP2:CHD1L",1
244,DOLP,1
245,(Glc)1 (GlcNAc)2 (Man)9 (PP-Dol)1,1
246,(GlcNAc)2 (Man)9 (PP-Dol)1,1
247,DbGP,1
248,AdoHcy,9
249,pre-rRNA containing 7-methylG-1639,2
250,AdoMet,9
251,pre-rRNA,2
252,18SE pre-rRNA containing 1-methylpseudoU-1248,1
253,pre-rRNA containing pseudouridine,1
254,Mother filament:branching complex,1
255,F-actin,1
256,"WAVE2, WASP, N-WASP:ARP2/3 complex:G-actin",1
257,cytosolic FGFR1 fusion mutant dimers,2
258,cytosolic FGFR1 fusion mutants,1
259,PG,4
260,cytosolic PDGFR fusion dimers,3
261,cytosolic PDGFR fusions,2
262,BBS1,2
263,BBS9,2
264,BBS4,2
265,TTC8,2
266,BBS7,2
267,BBS5,2
268,BBIP1,2
269,BBS2,2
270,NAd,2
271,Ile-tRNA(Ile),1
272,adenosine 5'-monophosphate,3
273,tRNA(Ile),1
274,L-Ile,1
275,Intermediate 1,1
276,TIMMDC1,1
277,IP subcomplex,1
278,NDUFAF4,1
279,NDUFAF3,1
280,heme A,1
281,heme O,1
282,tRNA containing 1-methylG-9,1
283,tRNA containing G-9,1
284,tRNA containing 1-methylA-9,1
285,tRNA containing A-9,1
286,12S rRNA containing 5-methylC-841,1
287,12S rRNA,1
288,TFR2 dimer:2xholoTF,1
289,holoTF,1
290,TFR2,1
291,RUNX2:HDAC4,1
292,RUNX2,2
293,HDAC4,1
294,Ligand:GPCR complexes that activate G12/13:Heterotrimeric G-protein G12/13 (inactive).,1
295,G-protein G12/G13 (inactive),1
296,Ligand:GPCR complexes that activate G12/13,1
297,CTF1:LIFR:JAKs,1
298,CTF1,1
299,JAKs:LIFR,1
300,"RRAD gene:EGR1,EGR2",1
301,"EGR1,EGR2",1
302,RRAD gene,1
303,RRAD gene:EGR2:NAB2:CHD4,1
304,RRAD gene:EGR2,1
305,CHD4,1
306,NAB2,1
307,"PI5P, PI3P, PI(3,5)P2",1
308,"PI(4,5)P2, PI(3,4)P2, PI(3,4,5)P3",1
309,VLDL:PCSK9,1
310,VLDLR,3
311,PCSK9,1
312,DOXOL,2
313,DOX,2
314,"p-S15,S20-TP53 Tetramer:POU4F2",1
315,"p-S15,S20-TP53 Tetramer",3
316,POU4F2,1
317,25OH-CHOL,2
318,cAMP,2
319,DIGX,2
320,β3-agonists:ADBR3,1
321,β3-agonists,1
322,ADRB3,1
323,high kinase activity BRAF mutants:scaffold:MAP2K:MAPK complex,1
324,MAP2K homo/heterodimers,1
325,MAPKs,1
326,"high kinase activity BRAF mutants:scaffold:p-2S MAP2K:p-T,Y MAPK complex",1
327,THMN,4
328,EF:LF:(PA63:ANTXR2 oligomer),1
329,EF,2
330,PA63:ANTXR2 oligomer,1
331,LF,2
332,EF:LF:(PA63:ANTXR1 oligomer),1
333,PA63:ANTXR1 oligomer,1
334,"17(S)-HDPAn-6, 10(S),17(S)-diHDPAn-6",1
335,DPAn-6,1
336,"3' short overhanging ssDNA-DSBs:p-MRN:p-S1981,Ac-K3016-ATM:KAT5:BRCA1-C complex",1
337,"DNA DSBs:p-MRN:p-S1981,Ac-K3016-ATM:KAT5:p-BRCA1-C complex",1
338,Extended microhomologous 3'-ssDNA overhangs-DSB:MRN:RBBP8:LIG3:XRCC1,2
339,Extended microhomologous 3'-ssDNA overhangs-DSB:MRN:RBBP8,1
340,LIG3:XRCC1,2
341,MRN,1
342,RBBP8 homotetramer,1
343,dsDNA with base substitutions and inter-MMEJ deletion,1
344,Mal-CoA,1
345,cytosolic p-Y PDGFR fusion dimers,1
346,"I(1,3,4)P3",1
347,"I(1,3,4,5)P4",1
348,pY177-BCR-pY-FGFR1 mutant:GRB2:p-GAB1:PI3K,1
349,p-Y177-BCR-pY-FGFR1 mutant:GRB2:p-GAB2:PIK3R1,1
350,PIK3CA,2
351,p-FGFR1 mutant fusions:PI3K,1
352,p-FGFR1 fusion mutant dimers:PIK3R1,1
353,FGFR1 fusion mutant dimers:TKIs,1
354,Tyrosine kinase inhibitors of FGFR1 fusion mutants,1
355,basal body:transition zone proteins,1
356,Tectonic-like complex,1
357,NPHP complex,1
358,basal body,1
359,"ADORA1,3:Ade-Rib",3
360,"ADORA1,3",3
361,Ade-Rib,5
362,LPL,4
363,HSPG,4
364,VLDL:VLDLR,2
365,VLDL,5
366,Vitronectin:Plasminogen activator inhibitor 1,4
367,SERPINE1,10
368,VTN,4
369,Factor IIa inhibitors (peptide):IIa,5
370,Factor IIa inhibitors (peptide),5
371,activated thrombin (factor IIa),14
372,Factor IIa inhibitors (compounds):IIa,4
373,Factor IIa inhibitors (compounds),4
374,factor Xa:Factor Xa inhibitors,4
375,Factor Xa inhibitors,8
376,factor Xa,4
377,Va:Xa:Factor Xa inhibitors,4
378,Va:Xa,4
379,p-S133-CREB1,3
380,CREB1,3
381,VKORC1 inhibitors:VKORC1 dimer,5
382,VKORC1 dimer,5
383,VKORC1 inhibitors,5
384,integrin alpha4beta1:VCAM1,1
385,Integrin alpha4beta1,1
386,VCAM1,1
387,BTNL2: activated T Cell surface,1
388,Activated T Cell surface,1
389,BTNL2,1
390,"HSPG2:FGF2(10-155), Fibronectn matrix, Transthyretin tetramer, PDGFA homodimer, PDGFB homodimer",1
391,HSPG2(22-4391),1
392,"FGF2(10-155), Fibronectn matrix, Transthyretin tetramer, PDGFA homodimer, PDGFB homodimer",1
393,"p-S196,T198,T200-RUNX2:CBFB",2
394,RUNX2:CBFB,2
395,PalmC-F3,4
396,sequestered tissue factor,4
397,Heparan sulfate chain(3),2
398,SO4(2-),4
399,Heparan sulfate chain(2),2
400,Heparan chain(1),2
401,Heparan sulfate chain(7),2
402,Heparan sulfate chain(5),2
403,GlcNAc,4
404,Heparan sulfate chain(4),2
405,CS/HS precursor,2
406,Heparan chain(2),2
407,FGFR1c P252X mutant dimers bound to FGFs,2
408,FGFR1c-binding FGFs,2
409,FGFR1c P252X mutants,2
410,FGFR2 ligand-independent mutants,2
411,"Tenascins C, R, (X, N):Lecticans",4
412,Lecticans,4
413,"Tenascins C, R, (X, N)",8
414,"Tenascins C, R, (X, N):Fibronectin matrix",4
415,Fibronectin matrix,4
416,TNC:Syndecan-3,4
417,TNC,4
418,Syndecan-3,4
419,"RUNX2:HEY1,HEY2,HES1",1
420,"HEY1,HEY2,HES1",1
421,spherical HDL:apoC-II:apoC-III:apoE,1
422,APOC2,1
423,spherical HDL,1
424,APOC3,1
425,APOE,1
426,APOBR dimer:VLDL,1
427,APOBR dimer,1
428,LCNs:lipids,1
429,LCNs,1
430,lipids,1
431,APOC4,1
432,"VLDL (-APOC1,C4)",1
433,APOC1,1
434,LSR trimer:VLDL,1
435,LSR trimer,2
436,LSR trimer:LDL,1
437,LRP1:Hemopexin:heme,1
438,LRP1,1
439,HPX:heme b,1
440,MSR1:Ligand,1
441,MSR1 (SCARA1) trimer,1
442,Ligands of MSR1,1
443,LDL:LRP8,1
444,LRP8,1
445,OLR1 bound to oxidized LDL,1
446,OLR1,1
447,LIPA-degraded LDL,1
448,CHOL,2
449,FA,1
450,arachidyl ester,1
451,Acyl-CoA,1
452,ARACOH,1
453,CHEST,1
454,SERPINE2:GAG:activated thrombin (factor IIa),1
455,SERPINE2:GAG,1
456,"5bCHOL3a,7a,12a,27-tetrol",1
457,"5bCHOL3a,7a,12a-triol",1
458,FAs,1
459,DAGs,1
460,TAGs,1
461,AGER ligands:AGER,1
462,AGER,1
463,AGER ligands,1
464,"ABCA1gene:NR1H2,3:RXR:NR1H2,3 ligands:NCOR:GPS2:TBL1:HDAC3",1
465,"ABCA1gene:NR1H2,3:RXR:NCOR:GPS2:TBL1:HDAC3",1
466,"hydroxyAsn-HIF1A,HIF2A",1
467,"HIF1A,HIF2A",1
468,HILPDA:lipid droplet,1
469,HILPDA,1
470,lipid droplet,1
471,"USP19:HIF1A,BIRC2,BIRC3",1
472,USP19,1
473,"HIF1A,BIRC2,BIRC3",1
474,HIF,1
475,HIF-alpha,1
476,ARNT,1
477,NICD1:HIF1A,1
478,HIF1A,4
479,NICD1,1
480,"p-S15,S20-TP53 Tetramer:CREBBP:BNIP3L Gene",1
481,CREBBP,1
482,BNIP3L Gene,1
483,E2F6:TFDP1/2:E2F1 gene,1
484,E2F1 gene,1
485,"E2F6:(TFDP1,TFDP2)",1
486,p-S17-FUNDC1:LC3,1
487,LC3,1
488,p-S17-FUNDC1,1
489,TWIST1:RUNX2 gene,1
490,RUNX2 gene,1
491,TWIST1,1
492,3SUMO1:VHL,1
493,UBE2I,2
494,VHL,1
495,SUMO1:C93-UBE2I,2
496,Nuclear Pore Complex (NPC),1
497,"p-MAPK8,9,10",2
498,"RBX1:NEDD8-CUL2:EloB,C:VHL:COMMDs:CCDC22:DCUN1D1,2,4,5:hydroxyPro-HIF-alpha",2
499,hydroxyPro-HIF-alpha,3
500,"RBX1:NEDD8-CUL2:EloB,C:VHL:COMMDs:CCDC22:DCUN1D1,2,4,5",2
501,"hydroxyPro-HIF-alpha:VHL:EloB,C:CUL2:RBX1",2
502,"VHL:EloB,C:CUL2:RBX1",1
503,"p-Y700,Y731,Y774-CBL",1
504,CBL,1
505,2xHP-HIF1A,2
506,"hydroxyPro-HIF-alpha:VHL:EloB,C:CUL2:RBX1:LIMD1,AJUBA,WTIP:PHD2,3",2
507,"PHD2,3:LIMD1,AJUBA,WTIP:VHL:EloB:EloC:CUL2:RBX1",1
508,"HIF1A,EPAS1:PTK6 Gene",1
509,PTK6 Gene,2
510,"HIF1A,EPAS1",1
511,"p-S15,S20-TP53 Tetramer:IGFBP3 Gene",1
512,IGFBP3 Gene,1
513,S100A1:TLR4:LY96,1
514,S100A1 dimer:Ca(2+),1
515,"E2F1:(TFDP1,TFDP2):RAD51 gene",1
516,"E2F1:(TFDP1,TFDP2)",1
517,RAD51 gene,1
518,SUMO1:NFKBIA,1
519,NFKBIA,1
520,"ub-HIF-alpha:VHL:EloB,C:CUL2:RBX1",1
521,"UBE2D1,2,3",3
522,"UBE2D1,2,3:Ubiquitin",3
523,"ub-hydroxyPro-HIF-alpha:VHL:EloB:EloC:NEDD8-CUL2:RBX1:COMMDs:CCDC22:DCUN1D1,2,4,5",1
524,"ub-hydroxyPro-HIF-alpha:VHL:EloB:EloC:CUL2:RBX1:LIMD1,AJUBA,WTIF:PHD2,3",1
525,"BMAL1:CLOCK,NPAS2",1
526,ARNTL,1
527,"CLOCK,NPAS2",1
528,HP-HIF3A,2
529,HIF3A,2
530,2xHP-EPAS1,2
531,EPAS1,3
532,DDIT4:14-3-3 dimer,1
533,14-3-3 dimer,1
534,DDIT4,1
535,KDM4B-regulated genes:H3K9me3 nucleosome:ESR1:ESTG:KDM4B,1
536,ESR1:ESTG,1
537,KDM4B,1
538,KDM4B-regulated genes:H3K9me3 nucleosome,1
539,p-S52-EIF2S1:EIF2S2:EIF2S3,1
540,EIF2S1:EIF2S2:EIF2S3,1
541,HGF dimer:MET,1
542,MET,1
543,HGF dimer,1
544,ULK1,2
545,FUNDC1,1
546,p-S13-FUNDC1,1
547,EDN1,1
548,EDN1(53-90),1
549,MyrG-CDK5R1(2-98),1
550,CDK5R1(99-307),1
551,MyrG-CDK5R1(2-307),1
552,RvD5n-3DPA,2
553,oxidised acceptor,2
554,"7,17-diHp-DPAn-3",2
555,reduced acceptor,2
556,p-Y565-HIF1A,2
557,"p-Y565,S797-HIF1A",1
558,PTK6 Gene:EPAS1:NR3C1:Glucocorticoid ligand:PELP1,1
559,PELP1,1
560,"NR3C1:(ALDO,11DCORST,CORST,CORT) dimer",1
561,"RBX1:NEDD8-CUL2:EloB,C:VHL:COMMDs:CCDC22:DCUN1D1,2,4,5:UBXN7",1
562,UBXN7,1
563,CYGB dimer:O2,1
564,CYGB dimer,1
565,p-AMPK heterotrimer,1
566,AMPK heterotrimer,1
567,Gal,1
568,LacCer,1
569,Gb3Cer,1
570,Thrombin-activated PAR:Gq (active),3
571,GDP,7
572,GTP,7
573,Thrombin-activated PAR:Gq (inactive),3
574,P2X purinoreceptors:ATP,3
575,P2RX receptors,3
576,histidine-rich glycoprotein:plasminogen,6
577,PLG(20-810),6
578,HRG,6
579,NMP,3
580,NDP,6
581,"fibrin multimer, crosslinked:tissue plasminogen activator (one-chain):plasminogen activator inhibitor 1",3
582,"fibrin multimer, crosslinked:tissue plasminogen activator (one-chain)",3
583,"fibrin multimer, crosslinked:tissue plasminogen activator (two-chain):plasminogen activator inhibitor 1",3
584,"fibrin multimer, crosslinked:tissue plasminogen activator (two-chain)",3
585,factor Vi intermediate form,8
586,F5(535-737),4
587,factor Va,4
588,activated thrombin (factor IIa):SERPIND1,4
589,SERPIND1,4
590,DGL-CoA,3
591,Malonyl-CoA,3
592,GLA-CoA,3
593,F5(335-534),4
594,factor Vi,4
595,"PSGs:Proteoglycan,TGFB1",1
596,PSGs,1
597,"Proteoglycans,TGFB1",2
598,MST1 dimer,1
599,pro-MST1,1
600,NH3,1
601,"Cit3-replicative histone H3, Cit9-replicative histone H3, Cit18-replicative histone H3, Cit27-replicative histone H3",1
602,"MeR3-replicative histone H3, MeR9-replicative histone H3, MeR18-replicative histone H3, Me27-replicatve histone H3",1
603,"OSCAR:Collagen I,II,III/SP-D",1
604,"Collagen types I,II,III/SP-D",1
605,OSCAR,1
606,IFT B*,1
607,CLUAP,1
608,TTC26,1
609,IFT81,1
610,IFT172,1
611,IFT80,1
612,TRAF3IP1,1
613,RABL5,1
614,TTC30,1
615,HSPB11,1
616,IFT52,1
617,IFT74,1
618,IFT88,1
619,IFT46,1
620,IFT57,1
621,IFT27,1
622,AcK15-histone H3,1
623,Histone H3,2
624,Gal-Xyl-proteins,1
625,UDP-Gal,1
626,xylosyl-core proteins,1
627,Cleaved collagen type V fibril,1
628,Collagen V,1
629,Activated FGFR3 t(4;14) translocation mutants,1
630,FGFR3 (4;14) translocation mutant dimers,2
631,FGFR3 (4;14) translocation mutants,1
632,FGFR3 mutant dimers:TKIs,1
633,FGFR3 mutant dimers,1
634,Tyrosine kinase inhibitors of FGFR3 mutants,1
635,MeK28-histone H3,2
636,Me3K28-histone H3,1
637,Me2K28-histone H3,2
638,Centrosome:AURKA:TPX2:HMMR,1
639,HMMR,1
640,Centrosome:AURKA,1
641,TPX2,1
642,p21 RAS:GTP,4
643,p21 RAS:GDP,4
644,Activated FGFR1 mutants:FRS2,2
645,Activated FGFR1 mutants,1
646,FRS2,4
647,Activated FGFR3 mutants with enhanced kinase activity,1
648,FGFR3 point mutant dimers with enhanced kinase activity,2
649,Activated FGFR3 mutants:FRS2,2
650,Activated FGFR2 mutants:FRS2,2
651,Activated FGFR4 mutants:FRS2,2
652,Activated FGFR1 mutants:p-FRS2,1
653,Activated FGFR3 mutants:p-FRS2,1
654,Activated FGFR2 mutants:p-FRS2,1
655,Activated FGFR4 mutants:p-FRS2,1
656,FGFR3 point mutants with enhanced kinase activity,1
657,CMP,1
658,Type 2 MSGG,1
659,CMP-Neu5Ac,1
660,Type 2 chain,1
661,FGFR3 cysteine mutant dimers,1
662,FGFR3 cysteine mutants,1
663,p-S456-ABL1,2
664,ABL1,2
665,p-S15-TP53 Tetramer,2
666,TP53 Tetramer,2
667,"DNA DNA DSBs:p-MRN:p-S1981,Ac-K3016-ATM:KAT5:K63PolyUb-K14,K16,p-S139-H2AFX,Me2K21-HIST1H4A-Nucleosome:p-5T-MDC1:p-S102-WHSC1:RNF8:Zn2+:SUMO1:p-T4827-HERC2:UBE2N:UBE2V2:RNF168:PIAS4:p-S25,S1778-TP53BP1:p-4S,2T-BRCA1-A complex",2
668,p-T68-CHEK2,2
669,"DNA DNA DSBs:p-MRN:p-S1981,Ac-K3016-ATM:KAT5:K63PolyUb-K14,K16,p-S139-H2AFX,Me2K21-HIST1H4A-Nucleosome:p-5T-MDC1:p-S102-WHSC1:RNF8:Zn2+:SUMO1:p-T4827-HERC2:UBE2N:UBE2V2:RNF168:PIAS4:p-S25,S1778-TP53BP1:p-4S,2T-BRCA1-A complex:CHEK2",2
670,"DNA DNA DSBs:p-MRN:p-S1981,Ac-K3016-ATM:KAT5:K63PolyUb-K14,K16,p-S139-H2AFX,Me2K21-HIST1H4A-Nucleosome:p-5T-MDC1:p-S102-WHSC1:RNF8:Zn2+:SUMO1:p-T4827-HERC2:UBE2N:UBE2V2:RNF168:PIAS4:p-S25,S1778-TP53BP1:RIF1:PAXIP1",2
671,p-S645-DCLRE1C,2
672,"DNA DNA DSBs:p-MRN:p-S1981,Ac-K3016-ATM:KAT5:K63PolyUb-K14,K16,p-S139-H2AFX,Me2K21-HIST1H4A-Nucleosome:p-5T-MDC1:p-S102-WHSC1:RNF8:Zn2+:SUMO1:p-T4827-HERC2:UBE2N:UBE2V2:RNF168:PIAS4:p-S25,S1778-TP53BP1:RIF1:PAX1IP:DCLRE1C",2
673,DNA DSBs:MRN:Ac-K3016-ATM dimer:KAT5,2
674,"DNA DSBs:MRN:p-S1981,Ac-K3016-ATM:KAT5",2
675,"p-S1981,Ac-K3016-ATM",2
676,ATM:PEX5,8
677,ATM dimer:p-PEX5,2
678,ATM dimer:PEX5,4
679,ATM,4
680,PEX5,2
681,MRE11:dsDNA,2
682,Double-stranded DNA,2
683,MRE11A,2
684,BT-CoA,2
685,BUT,2
686,Gly,2
687,Na+/Li+,4
688,20-HETE,2
689,ARA,4
690,19-HETE,2
691,AGT(34-43),5
692,AGT,3
693,TACR3:TAC3,1
694,TACR3,1
695,TAC3,1
696,AGT(34-41),2
697,NTS(151-160),1
698,NTS(161-163),1
699,NTS(151-163),1
700,"ADORA2A,B:Ade-Rib",1
701,"ADORA2A,B",1
702,ADORA2B:Ade-Rib,1
703,ADORA2B,1
704,PI3K Inhibitors:PI3K,1
705,"PI3K mutants,Activator:PI3K",1
706,PI3K inhibitors,1
